Reckitt Deals Feed OTC Domination Plan
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.
You may also be interested in...
Bristol-Myers Squibb Sells French Consumer Health Unit UPSA To Taisho For $1.6bn
Bristol-Myers Squibb has joined the big pharma trend of divesting non-core assets to focus on high-margin prescription drugs by agreeing to sell over-the-counter drugs business UPSA for $1.6bn to Japanese healthcare firm Taisho Pharmaceutical.
European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati
Bristol-Myers Squibb weighs selling its UPSA French OTC business, conducting a strategic review to assess its growth potential. Milan-based Recordati, says it plans to grow its OTC business; the firm sold a 51.8% stake owned by the Recordati family to a consortium of private equity funds for $3.56bn.
European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati
Bristol-Myers Squibb weighs selling its UPSA French OTC business, conducting a strategic review to assess its growth potential. Milan-based Recordati, says it plans to grow its OTC business; the firm sold a 51.8% stake owned by the Recordati family to a consortium of private equity funds for $3.56bn.